The role of empagliflozin-induced metabolic changes for cardiac function in patients with type 2 diabetes. A randomized cross-over magnetic resonance imaging study with insulin as comparator

Autor: Roopameera Thirumathyam, Erik Arne Richter, Gerrit van Hall, Jens Juul Holst, Mogens Fenger, Jens P. Gøtze, Ulrik Dixen, Niels Vejlstrup, Sten Madsbad, Per Lav Madsen, Nils Bruun Jørgensen

Publikováno v: Cardiovascular Diabetology, Vol 23, Iss 1, Pp 1-13 (2024)

Abstract Background Metabolic effects of empagliflozin treatment include lowered glucose and insulin concentrations, elevated free fatty acids and ketone bodies and have been suggested to contribute to the cardiovascular benefits of empagliflozin tre

Externí odkaz: https://doaj.org/article/94fbf6a45ebd4b38b014b914638e271b

876-P: Empagliflozin-Induced Metabolic Changes and Cardiac Function in Patients with Type 2 Diabetes: A Randomized Crossover MRI Study with Insulin as Comparator

Autor: ROOPAMEERA THIRUMATHYAM, JENS PETER GOETZE, JENS J. HOLST, NIELS VEJLSTRUP, STEN MADSBAD, PER L. MADSEN, NILS B. JØRGENSEN

Publikováno v: Diabetes. 71

Introduction: Empagliflozin reduces cardiovascular risk in type 2 diabetes, possibly through improved cardiac function associated with metabolic changes including lowered glucose and insulin concentrations and elevated free fatty acids (FFA) . We aim

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2db2fa3db8cffda8c12ea87e65a14f38
https://doi.org/10.2337/db22-876-p

Investigating the roles of hyperglycaemia, hyperinsulinaemia and elevated free fatty acids in cardiac function in patients with type 2 diabetes via treatment with insulin compared with empagliflozin: Protocol for the HyperCarD2 randomised, crossover trial

Autor: Roopameera Thirumathyam, Erik Arne Richter, Jens Peter Goetze, Mogens Fenger, Gerrit Van Hall, Ulrik Dixen, Jens Juul Holst, Sten Madsbad, Niels Vejlstrup, Per Lav Madsen, Nils Bruun Jørgensen

Publikováno v: Thirumathyam, R, Richter, E A, Goetze, J P, Fenger, M, van Hall, G, Dixen, U, Holst, J J, Madsbad, S, Vejlstrup, N, Madsen, P L & Jørgensen, N B 2022, ' Investigating the roles of hyperglycaemia, hyperinsulinaemia and elevated free fatty acids in cardiac function in patients with type 2 diabetes via treatment with insulin compared with empagliflozin: Protocol for the HyperCarD2 randomised, crossover trial ', B M J Open, vol. 12, no. 8, e054100 . https://doi.org/10.1136/bmjopen-2021-054100

IntroductionType 2 diabetes (T2D) is characterised by elevated plasma glucose, free fatty acid (FFA) and insulin concentrations, and this metabolic profile is linked to diabetic cardiomyopathy, a diastolic dysfunction at first and increased cardiovas

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::393290c37fa8709a7d577d34edecc716
https://curis.ku.dk/portal/da/publications/investigating-the-roles-of-hyperglycaemia-hyperinsulinaemia-and-elevated-free-fatty-acids-in-cardiac-function-in-patients-with-type-2-diabetes-via-treatment-with-insulin-compared-with-empagliflozin-protocol-for-the-hypercard2-randomised-crossover-trial(0dce619a-81fa-4546-8eb4-4193005a12e9).html